HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2–3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy

• Allison Martin ,

  * E-mail: SECONDLINE@kirby.unsw.edu.au

  Affiliation The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia

  ⨯
• Cecilia L. Moore,

  Affiliation The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia

  ⨯
• Patrick W. G. Mallon,

  Affiliation University College Dublin School of Medicine and Medical Science, Dublin, Ireland

  ⨯
• Jennifer F. Hoy,

  Affiliation The Alfred Hospital and Monash University, Victoria, Melbourne, Australia

  ⨯
• Sean Emery,

  Affiliation The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia

  ⨯
• Waldo H. Belloso,

  Affiliation Coordinación de Investigación Clínica Académica en Latinoamérica, Buenos Aires, Argentina

  ⨯
• Praphan Phanuphak,

  Affiliation Thai Red Cross AIDS Research Center, Bangkok, Thailand

  ⨯
• Samuel Ferret,

  Affiliation Hopital Saint-Louis, Paris, France

  ⨯
• David A. Cooper,

  Affiliation The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia

  ⨯
• Mark A. Boyd,

  Affiliation The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia

  ⨯
• on behalf of the Second-line study team